European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

ECTRIMS is dedicated to the understanding and treatment of multiple sclerosis (MS). Learn more below

Through our Patient Community Hub, we connect people living with MS and related conditions with trusted, up-to-date scientific information. The Patient Community Hub empowers those affected by MS, NMOSD, and MOGAD. By bringing patients, families, and experts together, we ensure no one faces these challenges alone, providing a consistent resource for connection and education.

05/06/2026

𝘞𝘩𝘢𝘵 𝘪𝘴 𝘪𝘵 𝘳𝘦𝘢𝘭𝘭𝘺 𝘭𝘪𝘬𝘦 𝘵𝘰 𝘵𝘢𝘬𝘦 𝘱𝘢𝘳𝘵 𝘪𝘯 𝘢𝘯 𝘔𝘚 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘵𝘳𝘪𝘢𝘭?

For many people living with MS, research can feel distant or difficult to understand. But for Helena Jidborg Alexander of Multiple Sclerosis Trust and George Pepper of Shift.ms, getting involved in clinical trials and patient involvement projects became a source of hope, purpose, and connection.

In our latest ECTRIMS Community Voices article, they share:

🔹 What motivated them to join research studies

🔹 What the clinical trial experience was actually like

🔹 How patient voices are changing MS research

🔹 Why diversity and inclusion in research matter

How involvement can help people feel empowered and hopeful about the future.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲 𝐡𝐞𝐫𝐞: https://bit.ly/4udVZsK

04/06/2026

🎧 New Podcast Episode: The 2024 McDonald Criteria — Will They Reduce MS Misdiagnosis?

The revised 2024 McDonald Criteria represent one of the most important updates in multiple sclerosis diagnosis in recent years — but will they improve diagnostic accuracy in real-world clinical practice?

In this ECTRIMS Podcast episode, recorded in collaboration with the Multiple Sclerosis Journals “Controversies in MS” series, Prof. Anneke van der Walt speaks with Prof. Andy Solomon from University of Vermont and Prof. Enrique Gomez Figueroa from Hospital Civil de Guadalajara about the promises and challenges of the revised criteria.

𝐓𝐡𝐞 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐞𝐱𝐩𝐥𝐨𝐫𝐞𝐬:

🔹 Central vein sign (CVS) and paramagnetic rim lesions (PRLs)

🔹 MRI interpretation and diagnostic specificity

🔹 Risks of overdiagnosis and false positives

🔹 Global implementation challenges and healthcare equity

🔹 The future role of AI in MS imaging

As MS diagnosis evolves, balancing earlier diagnosis with diagnostic accuracy remains one of the field’s greatest challenges.

🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:

𝐒𝐩𝐨𝐭𝐢𝐟𝐲: https://bit.ly/3RJywCs
𝐀𝐩𝐩𝐥𝐞: https://apple.co/4obJlcz
𝐖𝐞𝐛𝐬𝐢𝐭𝐞: https://bit.ly/4dP9ydu

This episode is part of the MS Journal Controversies in MS series on The revised 2024 McDonald criteria can solve the misdiagnosis problem in MS. The accompanying Yes, No, and Commentary articles are available to read open access for the next month, compliments of MS Journal.

30/05/2026

🌍Today is , a day of global solidarity to build informed, caring communities and systems that support people diagnosed with MS.

This year's theme, , is a reminder that a diagnosis isn't just a medical moment: It's a life-changing one. And patients are not alone in it.

♦️ More than 2.9 million people worldwide are living with multiple sclerosis (MS)

♦️ Every 5 minutes, someone, somewhere receives a new MS diagnosis

At ECTRIMS, we join the international community in calling for global action to improve early and accurate multiple sclerosis diagnosis for everyone, everywhere.

𝐘𝐨𝐮𝐫 𝐬𝐭𝐨𝐫𝐲 𝐦𝐚𝐭𝐭𝐞𝐫𝐬. To participate in highlighting :

🎨 Join the Multiple Sclerosis International Federation and create a 𝐖𝐨𝐫𝐥𝐝 𝐌𝐒 𝐃𝐚𝐲 𝐩𝐨𝐬𝐭𝐞𝐫: https://bit.ly/4efFs3i

🔬 Have your say in the CURE-MS survey: https://bit.ly/4tXl1w7

📩 Stay connected with the MS community by signing up for the Patient Community Day Newsletter: https://bit.ly/49tftCp

29/05/2026

With taking place this weekend, Jon Strum and Dr. Nancy Sicotte sit down on RealTalk MS to discuss everything you need to know in the first 100 days after an . From the right questions to ask, to building your care team and learning how to advocate for yourself, this episode is packed with practical guidance to help you move forward with confidence.

🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐡𝐞𝐫𝐞: http://realtalkms.com/456

22/05/2026

🔍 𝐂𝐚𝐧 𝐰𝐞 𝐫𝐞𝐯𝐞𝐫𝐬𝐞 𝐧𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐝𝐚𝐦𝐚𝐠𝐞 𝐢𝐧 𝐌𝐒?

Our latest Spotlight, 𝘚𝘵𝘰𝘱𝘱𝘪𝘯𝘨 𝘋𝘪𝘴𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘗𝘳𝘰𝘨𝘳𝘦𝘴𝘴𝘪𝘰𝘯 𝘙𝘦𝘮𝘢𝘪𝘯𝘴 𝘵𝘩𝘦 𝘒𝘦𝘺 𝘊𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦, explores the latest research into neuroprotection and repair in MS.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐡𝐞𝐫𝐞: https://bit.ly/43mtHkU

"Progression independent of disease activity is the most important problem that we need to solve," said Professor Ludwig Kappos at ECTRIMS 2025.

"We observed that the infusion of autologous bone marrow was associated with reduced rate in change of the global evoked potential at 12 months," adds Dr. Claire Rice of the University of Bristol.

The ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania de Vito, PhD.

21/05/2026

Is curing multiple sclerosis possible and how is a "cure" defined? CURE-MS is a study aimed at answering these questions and reaching consensus. CURE-MS is a modified Delphi panel study using a multistakeholder approach, which includes MS neurologists, patients, patient advocates and industry representatives.

CURE-MS wants to hear from you! 👉https://redcap.uza.be/studies/surveys/?s=KD4LJTKYN4TKTAHH

⏰ The survey takes no more than 15 minutes. The pre-Delphi round is open until 31 May 2026.

The steering committee of CURE-MS is comprised of:

• Antonia Lefter, University of Antwerp, Belgium, University of Oxford, UK
• Georgina Arrambide, CEMCAT (Centre d'Esclerosi Múltiple de Catalunya), Hospital Universitari Vall d'Hebron, Spain
• Yolanda Blanco, Hospital Clínic de Barcelona, Spain
• Radu Tanasescu, Nottingham University Hospitals, UK
• Hélène Zéphir, CHU de Lille, France
• Paola Zaratin, Italian MS Society Foundation, Italy
• Barbara Willekens, UZA and University of Antwerp, Belgium

All data collection and management related to this survey are handled solely by the initiative organisers. ECTRIMS is not responsible for the management of data collected through partner initiatives.

15/05/2026

🎧 New Podcast Episode: EBV and Multiple Sclerosis – Could Infection Hold the Key to MS?

The link between Epstein–Barr virus (EBV) and multiple sclerosis has rapidly become one of the most important areas of investigation in MS research.

In this new ECTRIMS Podcast episode, Prof. Gavin Giovannoni from Queen Mary University of London and Prof. Tomas Olsson from Karolinska Institutet join Brett Drummond to explore the latest evidence connecting EBV infection to MS development, progression, and future therapeutic strategies.

The discussion covers:
🔹 Molecular mimicry and autoimmune activation
🔹 EBV persistence and chronic CNS inflammation
🔹 Antiviral therapies and CAR-T approaches
🔹 The future of EBV-targeted vaccines
🔹 Potentially lowering MS risk by preventing infectious mononucleosis

🎧 Listen now — links in the comments.

08/05/2026

🌍 Your experience matters.

Multiple Sclerosis International Federation (MSIF) has launched a World MS Day poster maker that lets you create your own personal diagnosis poster. You can also choose to anonymously share your experience to help build a global picture of what it means to be diagnosed with MS.

Every story is different - and yours could help improve understanding of MS diagnosis experiences worldwide, including the barriers people face across different countries.

We are proud to support this initiative. Create your poster today and be part of the global MS community.

𝐂𝐫𝐞𝐚𝐭𝐞 𝐲𝐨𝐮𝐫 𝐩𝐨𝐬𝐭𝐞𝐫 𝐡𝐞𝐫𝐞: https://worldmsday.org/poster-maker/

30/04/2026

Living with multiple sclerosis means navigating a lot of information — and you don’t have to do it alone.

𝐒𝐢𝐠𝐧 𝐮𝐩 𝐭𝐨 𝐨𝐮𝐫 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐧𝐞𝐰𝐬𝐥𝐞𝐭𝐭𝐞𝐫 𝐭𝐨 𝐫𝐞𝐜𝐞𝐢𝐯𝐞:

· Clear updates on the latest MS research

· Information about upcoming Patient Community Day events

· Practical insights you can use in everyday life

· News from MS organisations and regional partners around the world

Stay informed. Stay connected. Be part of a global MS community.

𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 𝐡𝐞𝐫𝐞: https://bit.ly/4jv47Bv

22/04/2026

Breaking news podcast: fenebrutinib in relapsing MS

New Phase 3 data presented at shows that fenebrutinib significantly reduces relapsing disease activity compared to teriflunomide — positioning it as a potential high-efficacy oral therapy.

In this episode, Prof. Ludwig Kappos from Universitätsspital Basel & Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Dr. Jiwon Oh from University of Toronto & Unity Health Toronto discuss the full FENhance 1 & 2 trial results with host Brett Drummond MStranslate.

🎧 𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:
Spotify https://bit.ly/42kelwL
Apple: https://apple.co/4tsuvjR
Website: https://bit.ly/4eBsRYg

Watch this space! For those interested in learning more, the full trial results is expected to be published in the coming months.

Universitätsspital Basel, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Toronto

Unity Health Toronto, Barlo MS Centre

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/, https://www.ectrimspatientcommunity.eu/, https://www.linkedin.com/company/ectrims/, https://x.co

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Verknüpfungen

Wollen Sie Ihr Praxis zum Top-Klinik in Basel machen?